Department of Hematology, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou Province, China.
Nursing College, Zunyi Medical University School of Medicine and Technology, Zunyi, Guizhou Province, China.
Medicine (Baltimore). 2022 Jun 17;101(24):e29179. doi: 10.1097/MD.0000000000029179.
Persistent leukocytosis with megalosplenia is a common manifestation among patients with myeloproliferative neoplasm (MPN), especially for chronic myeloid leukemia (CML) patients. Here, we report a rare case of myeloid neoplasm with BCR-PDGFRA rearrangement characterized by obvious elevation of leukocyte count and megalosplenia.
A 32-year-old man presented with persistent leukocytosis and megalosplenia.
This patient was characterized by increased leukocyte count and megalosplenia, and was clinically diagnosed as CML. However, the BCR/ABL fusion gene of the patient was negative, which did not support CML. Moreover, the results of the karyotype showed 46, XY, t(4;22)(q12;q11) and RT-PCR + Sanger detection showed positive PDGFA/BCR. Accordingly, the diagnosis of myeloid neoplasm with BCR-PDGFA rearrangement was confirmed.
This patient was initially received imatinib (400 mg) orally once a day, and the dosage was adjusted to 100 mg owing to suffering from grade IV bone marrow suppression.
Hematological remission was achieved after 2 weeks, the best treatment response was achieved after 3 months, and the main molecular biological response was achieved after 12 months.
This case suggests that rare PDGFA fusion genes screening for patients comorbid with leukocytosis and megalosplenia is necessary to avoid misdiagnosis. Unlike other rearrangements of PDGFRA, the clinical manifestations of BCR-PDGFRA rearrangement are resembling CML without eosinophilia increase.
持续性白细胞增多伴巨脾是骨髓增殖性肿瘤(MPN)患者的常见表现,尤其在慢性髓性白血病(CML)患者中更为常见。在此,我们报告一例伴有 BCR-PDGFRA 重排的髓系肿瘤罕见病例,其特征为白细胞计数明显升高伴巨脾。
一名 32 岁男性因持续性白细胞增多和巨脾就诊。
该患者表现为白细胞计数增多伴巨脾,临床诊断为 CML。然而,患者的 BCR/ABL 融合基因阴性,不支持 CML。此外,染色体核型结果显示 46,XY,t(4;22)(q12;q11),RT-PCR+Sanger 检测显示 PDGFA/BCR 阳性。因此,确诊为伴有 BCR-PDGFA 重排的髓系肿瘤。
该患者最初接受伊马替尼(400mg)每日口服一次,因发生 4 级骨髓抑制,剂量调整至 100mg。
治疗 2 周后达到血液学缓解,3 个月时达到最佳治疗反应,12 个月时达到主要分子生物学反应。
该病例提示对于伴白细胞增多和巨脾的患者,有必要进行罕见 PDGFA 融合基因筛查,以避免误诊。与 PDGFRA 的其他重排不同,BCR-PDGFRA 重排的临床表现类似于无嗜酸性粒细胞增多的 CML。